Program Objective:
The goal of this program is to support translational research projects that address unmet clinical needs and have a realistic path to delivering improvements in health care. Examples of desirable outcomes include: improved diagnosis and treatment of disease through new medical devices; new biomarkers or diagnostics; new therapeutic targets and agents; or new clinical adoption of developed tools. It is expected that outcomes from funded projects will result in new intellectual property, industry partnerships, license deals and/or the creation of a start-up companies.
Program Overview:
- Fund established in 2008
- Follow-on funding to advance funded projects: $21,815,063M
- 330 applications have been received to date
- 66 projects have been funded with 19 project renewals, 1 pilot project
- Average award size is $80,000 ($100K starting in 2020)
- Active patent applications: none in 2022
- Total transactions to date: 44 2022: 1 executed and 4 under CDA discussion
- Total Presentations & Publications: 153
- 10 presentations & 4 publications in 2022
Start-up companies launched catalyzed by after receiving Ivy Biomedical Innovation Funding: 9
2 companies currently in active discussions to launch in 2023
- PS Fertility (new in 2022)
- Advaray, Inc. (formerly BrachyFoam, LLC)
- EpiEP
- GenEp
- KeViRx
- RetiVue
- SoundPipe
- Sphynkx (no longer active)
- Tear Solutions